Please assess the completion status of the following clinical trial:

Trial Title: Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ruptured saccular aneurysm repaired by neurosurgical clipping~2. Subarachnoid hemorrhage on computed tomography (CT) scan of grade 2-4 on the modified Fischer scale~3. WFNS grade 1 or 2 assessed during the Pre-randomization Phase. If WFNS grade 2, must not require an EVD prior to aneurysm repair~Exclusion Criteria:~1. Major complication during aneurysm repair such as, but not limited to, massive intraoperative hemorrhage, brain swelling, arterial occlusion or inability to secure the ruptured aneurysm~2. Angiographic vasospasm prior to randomization~3. Evidence of cerebral infarction with neurological deficit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EG-1962 Group (Type: EXPERIMENTAL): 1 dose of intracisternal EG-1962 (nimodipine microparticles) 600 mg
- Enteral Nimodipine Group (Type: ACTIVE_COMPARATOR): Up to a total of 21 days of enteral nimodipine (including nimodipine received prior to randomization)

Based on this trial design, predict the completion outcome and termination type (if applicable).